Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report)'s share price passed below its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $1.74 and traded as low as $1.7050. Lexicon Pharmaceuticals shares last traded at $1.72, with a volume of 2,018,984 shares traded.
Analysts Set New Price Targets
Several research firms have weighed in on LXRX. Wall Street Zen upgraded Lexicon Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Sunday, November 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Lexicon Pharmaceuticals in a research report on Wednesday, October 21st. Zacks Research cut Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Monday, August 3rd. Citigroup upped their price target on Lexicon Pharmaceuticals from $3.10 to $3.40 and gave the stock a "buy" rating in a research note on Monday, November 9th. Finally, Cantor Fitzgerald assumed coverage on Lexicon Pharmaceuticals in a report on Monday, September 28th. They set an "overweight" rating and a $8.00 price objective on the stock. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $5.80.
Check Out Our Latest Stock Report on LXRX
Lexicon Pharmaceuticals Stock Performance
The company has a market cap of $765.80 million, a P/E ratio of -12.28 and a beta of 1.10. The company has a quick ratio of 10.56, a current ratio of 10.62 and a debt-to-equity ratio of 0.32. The stock's 50-day moving average price is $1.74 and its 200 day moving average price is $1.90.
Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.03. The business had revenue of $11.25 million during the quarter, compared to analysts' expectations of $4.14 million. Lexicon Pharmaceuticals had a negative net margin of 161.80% and a negative return on equity of 35.76%. As a group, research analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.16 EPS for the current fiscal year.
Insider Transactions at Lexicon Pharmaceuticals
In other news, CEO Michael Exton bought 30,064 shares of the company's stock in a transaction that occurred on Friday, November 6th. The shares were purchased at an average price of $1.66 per share, for a total transaction of $49,906.24. Following the acquisition, the chief executive officer directly owned 328,496 shares of the company's stock, valued at $545,303.36. The trade was a 10.07% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 14.00% of the company's stock.
Institutional Investors Weigh In On Lexicon Pharmaceuticals
Hedge funds have recently bought and sold shares of the company. Siren L.L.C. increased its stake in shares of Lexicon Pharmaceuticals by 13.8% in the first quarter. Siren L.L.C. now owns 44,303,518 shares of the biopharmaceutical company's stock worth $69,113,000 after purchasing an additional 5,384,615 shares during the period. Renaissance Technologies LLC lifted its position in shares of Lexicon Pharmaceuticals by 508.0% during the 1st quarter. Renaissance Technologies LLC now owns 1,600,500 shares of the biopharmaceutical company's stock worth $2,497,000 after purchasing an additional 1,337,246 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Lexicon Pharmaceuticals during the 2nd quarter worth about $1,365,000. Bank of America Corp DE lifted its position in shares of Lexicon Pharmaceuticals by 415.3% during the 1st quarter. Bank of America Corp DE now owns 526,103 shares of the biopharmaceutical company's stock worth $821,000 after purchasing an additional 424,006 shares during the last quarter. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Lexicon Pharmaceuticals during the 1st quarter worth about $1,170,000. 74.70% of the stock is currently owned by institutional investors.
Lexicon Pharmaceuticals Company Profile
(
Get Free Report)
Lexicon Pharmaceuticals is a biopharmaceutical company based in The Woodlands, Texas. Founded in 1995 as Lexicon Genetics, the company uses drug discovery and development research to create medicines for serious diseases, with a focus on areas of unmet medical need. Its commercial product, Inpefa (sotagliflozin), is approved in the United States to reduce the risk of cardiovascular death and worsening heart failure in adults with heart failure. Lexicon also develops investigational medicines, including candidates studied for neuropathic pain and other conditions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Lexicon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexicon Pharmaceuticals wasn't on the list.
While Lexicon Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.